HOME
Lead Program
- Details
- Written by: web web
- Category: Home
- Hits: 644
Lead Program
Lead Program
Gain’s lead drug candidate GT-02287 is a best-in-class small molecule, for the treatment of GBA-Parkinson’s disease and other neurodegenerative diseases. GT-02287 is currently being evaluated in a Phase I clinical study.
Lead Program >>